Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Hims & Hers Accelerates AI Preventive Care and Platform Strategy
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
HIMS is accelerating AI-driven preventive care with new menopause, low testosterone and multi-cancer testing, deepening its personalized digital health platform.
Read More
Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?
Published: February 20, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Hims & Hers Health ( NYSE:HIMS ) just made a bold move to take its personalized wellness platform global.
Read More
Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint
Published: February 19, 2026 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) announced on Thursday that it has entered a definitive agreement to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. The acquisition is expected to strengthen Hims & Hers' international presence and expand its personalized healthcare offerings.
Read More
Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS fourth-quarter 2025 results are likely to benefit from new specialties and global expansion, but higher costs and GLP-1 scrutiny could cloud earnings.
Read More
Hims & Hers Health Stock Resumes Climb on Acquisition News
Published: February 19, 2026 by: Schaeffers Research
Sentiment: Positive
At last glance, shares of Hims & Hers Health Inc (NYSE:HIMS) are up 0.5% to trade at $15.91, after the wellness company announced its $1.15 billion acquisition of Australian digital health company Eucalyptus.
Read More
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
Read More
Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff
Published: February 16, 2026 by: 24/7 Wall Street
Sentiment: Negative
Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30 as of February 13.
Read More
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Negative
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.
Read More
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.
Read More
HIMS Selloff Creates De-Risked Entry
Published: February 11, 2026 by: Seeking Alpha
Sentiment: Negative
HIMS Selloff Creates De-Risked Entry
Read More
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade)
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Negative
Downgrading Hims & Hers Health, Inc. to Hold as the GLP-1 downside catalysts feel very real now. The FDA signaled new limits on non-approved compounded GLP-1 APIs being mass-marketed, and it explicitly called out Hims. Hims launched, then halted, an oral compounded semaglutide pill ($49) after two days; soon after, Novo sued for patent infringement, seeking an injunction and damages.
Read More
Novo Nordisk, Hims & Hers Health Shares React to Lawsuit
Published: February 09, 2026 by: Schaeffers Research
Sentiment: Negative
Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: February 09, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm.
Read More
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug market
Published: February 09, 2026 by: WSJ
Sentiment: Neutral
The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.
Read More
Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War
Published: February 09, 2026 by: Benzinga
Sentiment: Negative
Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much uncertainty.
Read More
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn
Published: February 09, 2026 by: Investopedia
Sentiment: Neutral
Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.
Read More
Hims & Hers is scrapping its plan for a knockoff Wegovy weight-loss pill. Here's why
Published: February 09, 2026 by: Fast Company
Sentiment: Negative
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss medications.Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month. Novo immediately threatened to sue Hims, and then the FDA said Friday that it plans to take decisive steps to limit access to the active …
Read More
HIMs 22% Collapse Looks Like A ‘Buy The Dip' Moment
Published: February 09, 2026 by: 24/7 Wall Street
Sentiment: Negative
Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9.
Read More
HIMS Slides 25% After NVO Sues Company Over Generic GLP-1 Pills
Published: February 09, 2026 by: Schwab Network
Sentiment: Negative
Legal issues hits Hims & Hers (HIMS). Novo Nordisk (NVO) filed a lawsuit against the company over allegedly selling unapproved Wegovy and Ozempic weight loss drugs.
Read More
Hims & Hers Falls Apart, Again
Published: February 09, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year.
Read More
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reason
Published: February 09, 2026 by: CNBC Television
Sentiment: Neutral
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the fight between Novo Nordisk and Hims & Hers over GLP-1 drugs, immunization policies in the U.S., and more.
Read More
Hims & Hers scraps low-cost weight-loss pill following backlash
Published: February 09, 2026 by: Proactive Investors
Sentiment: Negative
Hims & Hers scraps low-cost weight-loss pill following backlash Him & Hers (NYSE:HIMS) shares are set to open 23% lower at about $18 after the telehealth company announced over the weekend that it will stop offering a compounded oral version of semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, following regulatory scrutiny and industry backlash. “Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry,” Hims & Hers said in a statement on Saturday.
Read More
Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill
Published: February 06, 2026 by: Market Watch
Sentiment: Negative
Hims & Hers also said it's selling a cancer-detection test that's featured in its Super Bowl ad, which plays like a commentary on the wealthy's access to better healthcare.
Read More
Wall Street Roundup: Risk Off
Published: February 06, 2026 by: Seeking Alpha
Sentiment: Negative
Risk-off sentiment is driving sharp sell-offs in Bitcoin and major software stocks, with investors reallocating away from stretched tech valuations. AI-driven CapEx arms race at Alphabet (GOOGL) and Amazon (AMZN) is sparking concerns about profitability and sector disruption, despite strong revenue growth.
Read More
Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
Published: February 06, 2026 by: Reuters
Sentiment: Negative
Hims & Hers' gambit to sell a $49 compounded version of Novo Nordisk's Wegovy pill is rattling obesity shares, sparking debate about the legality of the move and threatening drugmaker returns in the burgeoning U.S. cash-pay market.
Read More
Hims & Hers Strengthens Platform-Led Digital Healthcare Model
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS is scaling a platform-led digital healthcare model with Labs, AI and YourBio Health, integrating diagnostics, data and care into one ecosystem.
Read More
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Negative
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
Read More
Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding' Over Cheaper Wegovy Version
Published: February 05, 2026 by: WSJ
Sentiment: Negative
Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637